<DOC>
	<DOCNO>NCT01765647</DOCNO>
	<brief_summary>Celiac disease ( CD ) autoimmune disease small intestine cause consumption gluten proteins widely use food source wheat , rye , barley . Exposure small intestine gluten cause inflammatory response , lead destruction intestine lining , often severe symptom include diarrhea , abdominal distention , fatigue , weight loss , anemia , neurological symptom . CD lifelong disease treatment currently available strict adherence life-time gluten free diet ( GFD ) . However , adhere diet difficult gluten protein find many food product . Therefore , gluten-free diet lifestyle financial implication individual thus potential impacting adversely quality life . Various approach study reduce need careful control diet CD , include use antibody IgY . IgY produce egg yolk super immunize laying hen . Egg yolk antibody natural product minimal toxicity , without egg allergy , offer low-cost , hygienic production study product . Once IgY antibody put capsule form , call AGY . Individuals CD recruit history biopsy proven CD , currently follow GFD continue mild moderate symptom relate gluten exposure , egg allergy . Blood test ATG antibody level screen . Those enrol 2 week run-in period diet symptom record , receive AGY capsule take meal 4 week period . Outcomes measure examine lab test result include antibody level , symptom , quality life .</brief_summary>
	<brief_title>Oral AGY Celiac Disease</brief_title>
	<detailed_description>The trial last approximately 6 week . Individuals screen ensure follow gluten free diet , continue mild moderate symptom gluten exposure despite diet , history biopsy proven celiac disease . Those meeting criterion baseline visit include short physical exam additional lab work safety measure , quality life questionnaire . They record diet symptom 2 week , return receive study medication , take meal . The first dose take clinic facilitate observation adverse effect . The next visit 2 week later blood work clinic visit , 2 week later final visit . Participants prompt report adverse event occur trial period completion trial . During trial period , study coordinator phone participant remind complete questionnaire inquire adverse event . All participant receive AGY capsule ( 500 mg per capsule ) , take 2 capsule meal . Outcome measure The primary outcome variable safety ( adverse event , lab result , symptom ) , measure throughout study . The secondary outcome ATG antibody level , measure visit .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>age 18 confirm diagnosis Celiac disease previous biopsy follow glutenfree diet ( GFD ) mild moderate symptom despite GFD diet diabetic use steroid previous year current use ASA/NSAIDs , metronidazole , misoprostol excess alcohol intake egg allergy history severe complication celiac disease chronic active GI disease pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Celiac disease</keyword>
	<keyword>AGY</keyword>
</DOC>